2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
Ann Rheum Dis. 2023 doi: 10.1136/ard-2022-223628
The first EULAR-endorsed points to consider (PtC) for the measurement and reporting of IFN-I assays in clinical research and practice are developed.
Assays measuring IFN-I pathway activation have not progressed into clinical practice, and uncertainty exists pertaining clinical applications. To help address this, Rodríguez-Carrio, et al. have formulated two overarching principles and 11 PtC, based on systematic review evidence and expert opinion, for the measurement and reporting of IFN-I pathway assays in clinical research and practice.
Keywords:
